Lilly's Retatrutide Achieves Phase 3 Success; FDA BLA Filing Planned Q1 2027

Eli Lilly said its investigational triple agonist retatrutide met primary endpoints in two pivotal Phase 3 studies (TRIUMPH-2 and TRIUMPH-3), producing substantial weight loss in adults with obesity with type 2 diabetes or cardiometabolic complications. The positive topline efficacy readout is a meaningful clinical validation step that can strengthen the near-to-mid term commercialization outlook for LLY’s obesity franchise.

Analysis

Eli Lilly said its investigational triple agonist retatrutide met primary endpoints in two pivotal Phase 3 studies (TRIUMPH-2 and TRIUMPH-3), producing substantial weight loss in adults with obesity with type 2 diabetes or cardiometabolic complications. The positive topline efficacy readout is a meaningful clinical validation step that can strengthen the near-to-mid term commercialization outlook for LLY’s obesity franchise.